Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 7 | 2025 | 2586 | 1.210 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 127 | 0.920 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 16 | 0.890 |
Why?
|
| Antibodies, Viral | 4 | 2024 | 306 | 0.840 |
Why?
|
| DNA, Mitochondrial | 1 | 2025 | 191 | 0.830 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2022 | 226 | 0.770 |
Why?
|
| Infectious Disease Medicine | 1 | 2020 | 3 | 0.670 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 44 | 0.610 |
Why?
|
| Medication Adherence | 1 | 2021 | 182 | 0.580 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 129 | 0.580 |
Why?
|
| Smoking | 1 | 2025 | 1024 | 0.560 |
Why?
|
| Neurons | 1 | 2025 | 1263 | 0.550 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 486 | 0.490 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 590 | 0.450 |
Why?
|
| Minority Groups | 1 | 2020 | 690 | 0.450 |
Why?
|
| Tennessee | 3 | 2022 | 93 | 0.360 |
Why?
|
| Viral Load | 2 | 2021 | 348 | 0.290 |
Why?
|
| Humans | 16 | 2025 | 43102 | 0.280 |
Why?
|
| Male | 8 | 2025 | 23409 | 0.250 |
Why?
|
| Adult | 8 | 2025 | 13872 | 0.240 |
Why?
|
| Adolescent | 5 | 2024 | 6081 | 0.230 |
Why?
|
| Infant | 3 | 2024 | 1175 | 0.220 |
Why?
|
| Young Adult | 4 | 2024 | 5080 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2001 | 44 | 0.200 |
Why?
|
| Child, Preschool | 2 | 2024 | 1546 | 0.190 |
Why?
|
| Sex Factors | 1 | 2025 | 1028 | 0.180 |
Why?
|
| Female | 8 | 2025 | 24698 | 0.180 |
Why?
|
| Transsexualism | 1 | 2021 | 20 | 0.180 |
Why?
|
| Child | 3 | 2024 | 3443 | 0.180 |
Why?
|
| Mitochondria | 1 | 2025 | 523 | 0.170 |
Why?
|
| Meningoencephalitis | 1 | 2001 | 14 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2001 | 23 | 0.170 |
Why?
|
| Achievement | 1 | 2020 | 24 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2020 | 83 | 0.160 |
Why?
|
| Cryptococcosis | 1 | 2001 | 43 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 74 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2020 | 121 | 0.160 |
Why?
|
| Cryptococcus neoformans | 1 | 2001 | 62 | 0.160 |
Why?
|
| Hydrocortisone | 1 | 2021 | 93 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 68 | 0.150 |
Why?
|
| Middle Aged | 4 | 2025 | 12222 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2019 | 139 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 518 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 760 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2019 | 195 | 0.130 |
Why?
|
| Poverty | 1 | 2020 | 400 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 706 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2020 | 719 | 0.100 |
Why?
|
| Haemophilus Infections | 1 | 1993 | 4 | 0.100 |
Why?
|
| Haemophilus influenzae | 1 | 1993 | 6 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 1993 | 8 | 0.100 |
Why?
|
| Knee Joint | 1 | 1993 | 12 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 1993 | 48 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2544 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2022 | 317 | 0.090 |
Why?
|
| Risk Factors | 1 | 2019 | 3994 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 376 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 367 | 0.080 |
Why?
|
| United States | 1 | 2020 | 5205 | 0.080 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2008 | 12 | 0.070 |
Why?
|
| Measles | 1 | 2008 | 7 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 74 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 117 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2008 | 196 | 0.060 |
Why?
|
| Aged | 1 | 2019 | 8214 | 0.060 |
Why?
|
| Meningitis, Bacterial | 1 | 2006 | 11 | 0.060 |
Why?
|
| Salmonella | 1 | 2006 | 12 | 0.060 |
Why?
|
| Salmonella Infections | 1 | 2006 | 16 | 0.060 |
Why?
|
| Continuity of Patient Care | 2 | 2021 | 120 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 7 | 0.050 |
Why?
|
| Case Management | 1 | 2021 | 24 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 48 | 0.040 |
Why?
|
| Autopsy | 1 | 2001 | 48 | 0.040 |
Why?
|
| Intestines | 1 | 2001 | 71 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 238 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 1604 | 0.040 |
Why?
|
| Myocardium | 1 | 2001 | 263 | 0.040 |
Why?
|
| Kidney | 1 | 2001 | 372 | 0.030 |
Why?
|
| Lung | 1 | 2001 | 492 | 0.030 |
Why?
|
| Hospitals, Municipal | 1 | 1996 | 2 | 0.030 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 1996 | 4 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 1996 | 35 | 0.030 |
Why?
|
| Tuberculosis | 1 | 1996 | 78 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1996 | 233 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 142 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 737 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1612 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2006 | 7 | 0.020 |
Why?
|
| Seizures | 1 | 2006 | 79 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 1772 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 432 | 0.010 |
Why?
|
| Models, Organizational | 1 | 1996 | 35 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 1996 | 32 | 0.010 |
Why?
|
| New York City | 1 | 1996 | 288 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1996 | 359 | 0.010 |
Why?
|